M atrial natriuretic peptide

N/A

Report date: 2026/03/13 20:02:36

Base Information

Drug NameM atrial natriuretic peptide
Drug Alias NameFrameshift ANPFrameshift atrial natriuretic peptidefsANPM-atrial natriuretic peptideMANP +[8] 
ClassificationBiologics
Mechanisms of ActionAldosterone antagonists
TargetsAldosterone
Therapy Area/IndicationsHypertensionOcular Hypertension
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesMayo Clinic
China Registration ClassN/A

Develop Information

Active CompaniesMayo ClinicE-Star BioTech LLC
Inactive CompaniesN/A
Active IndicationsHypertensionOcular Hypertension
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A